{"id":24792,"date":"2014-06-05T08:39:01","date_gmt":"2014-06-05T12:39:01","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=24792"},"modified":"2014-06-05T08:39:01","modified_gmt":"2014-06-05T12:39:01","slug":"valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792","title":{"rendered":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders?"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/05\/2014 (wallstreetpr) \u2013\u00a0Multinational, specialty pharmaceutical company <strong>Valeant Pharmaceuticals International Inc (NYSE:VRX)<\/strong> has recently boosted its aggressive unsolicited bid to buy another healthcare company, <b>Allergan, Inc. (NYSE:AGN)<\/b>, subject to the two sides engagement in negotiations to reach an agreement. Will Allergan management and its shareholders agree to Valeant Pharmaceuticals International\u2019s latest overtures?<\/p>\n<p style=\"text-align: justify;\"><b>Sweetened Bid<\/b><\/p>\n<p style=\"text-align: justify;\">Valeant Pharmaceuticals International Inc (NYSE:VRX)\u00a0lifted its open offer for Allergan to $72.00 in cash besides 0.83 Valeant Pharmaceuticals stock. However, the company attached a rider indicating that this deal is applicable only if Allergan engages in negotiation for a merger deal. In effect, the total offer value is lifted to $53.8 billion from $49.9 billion bid presented only a few days earlier. The earlier cash component was $58.30 per Allergan share.<\/p>\n<p style=\"text-align: justify;\">The development followed after Allergan\u2019s shareholder and hedge fund company, Perishing Square, who enjoys a 9.7% stake, agreed to part its stake in favor of Valeant Pharmaceuticals by opting to 100% stock consideration and forego cash component. The hedge fund company\u2019s CEO Bill Ackman said that he was ready to give up $600 million worth in favor of other shareholders in case Valeant Pharmaceuticals was ready to boost its bid to the other shareholders of Allergan. As a result, he will receive $20.75 a share less consideration compared to the other shareholders. This is probably meant to induce other Allergan shareholders to the unsolicited offer.<\/p>\n<p style=\"text-align: justify;\"><b>Valeant\u2019s Interest In Allergan<\/b><\/p>\n<p style=\"text-align: justify;\">The reason Valeant Pharmaceuticals International Inc (NYSE:VRX)\u00a0is more interested in buying Allergan could be that the merger has the potential to take it among the top five pharmaceutical companies by virtue of market capitalization by the turn of the year 2016. Although the likelihood of breaking up the company are also not ruled out. Valeant Pharmaceuticals is criticized for driving its growth through acquisitions rather than its own. Therefore, its interest in Botox manufacturer could very well be understood.<\/p>\n<p style=\"text-align: justify;\">Within a span of three days, Valeant Pharmaceuticals has boosted its bid on Allergan even before being asked to do so. However, this provides further room for lifting the bid price, though the chances of accepting Valeant Pharmaceuticals International Inc (NYSE:VRX)\u2019 bid have increased.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/05\/2014 (wallstreetpr) \u2013\u00a0Multinational, specialty pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) has recently boosted its aggressive unsolicited bid to buy another healthcare company, [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":24793,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2046,7115],"stock_ticker":[],"class_list":["post-24792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysevrx","tag-valeant-pharmaceuticals-international-inc-nysevrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders? - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders? - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/05\/2014 (wallstreetpr) \u2013\u00a0Multinational, specialty pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) has recently boosted its aggressive unsolicited bid to buy another healthcare company, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-05T12:39:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders?\",\"datePublished\":\"2014-06-05T12:39:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\"},\"wordCount\":374,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"keywords\":[\"NYSE:VRX\",\"Valeant Pharmaceuticals International Inc (NYSE:VRX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\",\"name\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders? - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"datePublished\":\"2014-06-05T12:39:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders? - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792","og_locale":"en_US","og_type":"article","og_title":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders? - Wall Street PR","og_description":"Boston, MA 06\/05\/2014 (wallstreetpr) \u2013\u00a0Multinational, specialty pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) has recently boosted its aggressive unsolicited bid to buy another healthcare company, [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-05T12:39:01+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders?","datePublished":"2014-06-05T12:39:01+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792"},"wordCount":374,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","keywords":["NYSE:VRX","Valeant Pharmaceuticals International Inc (NYSE:VRX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792","url":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792","name":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders? - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","datePublished":"2014-06-05T12:39:01+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Valeant-Pharmaceuticals-Intl-Inc.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/valeant-pharmaceuticals-intl-inc-nysevrx-will-its-sweetened-bid-enthuse-allergan-inc-nyseagn-shareholders-24792#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Will its Sweetened Bid Enthuse Allergan, Inc. (NYSE:AGN) Shareholders?"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=24792"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24792\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/24793"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=24792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=24792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=24792"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=24792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}